Dupixent (cutaneous T-cell lymphoma)
A new federal case group examines whether Dupixent, an eczema and asthma drug, may be connected to a rare skin lymphoma or delayed its diagnosis. The litigation is at an early stage.
- Case group
- MDL 3180
- Court
- D. New Jersey
- Centralized
- Jun 4, 2026
- Pending cases
- 38Oct 1, 2026
Where things stand
New to federal case groups? Read what an MDL is and how a mass tort claim works.
- Jun 4, 2026JPML centralized Dupixent CTCL cases against Regeneron, Sanofi and Genzyme.
Records that usually help
You don't need these to start. Don't upload them here. A firm will ask if it needs them.
- Pharmacy/specialty pharmacy fill history
- Dermatology records before and during Dupixent
- Skin biopsy and pathology reports
- Oncology/hematology records
About filing deadlines
Deadlines to file a claim vary by state and situation, and some may already have passed. Only a licensed attorney can tell you whether a deadline applies to you. Submitting here does not stop any deadline. Read how filing deadlines work.
Related campaigns
Attorney advertising. TortMatics (FusionByte Media LLC) is not a law firm. Information on this page is general and is not medical or legal advice. Talk to a doctor before changing any medication.